Published in Antimicrob Agents Chemother on October 01, 1991
Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1994) 0.87
Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother (1994) 0.87
The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol (1994) 0.86
Oral absorption of ofloxacin administered together with aluminum. Antimicrob Agents Chemother (1994) 0.75
The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. J Physiol (1954) 12.13
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother (1983) 3.53
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther (1989) 2.08
Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet (1988) 2.04
Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother (1989) 1.98
Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1987) 1.87
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother (1989) 1.74
Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. Drugs (1988) 1.48
Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother (1990) 1.38
Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother (1990) 1.28
Overview of drug interactions with the quinolones. J Antimicrob Chemother (1988) 1.18
[Decreased absorption of pefloxacin by gastric antacids. Preliminary study]. Presse Med (1986) 0.80
[Labeling of injectable drugs used in anesthesia]. Rev Esp Anestesiol Reanim (2011) 1.39
Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary. Am J Hosp Pharm (1990) 1.37
P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med (2006) 1.02
Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther (1996) 0.94
Sodium salicylate prevents paraquat-induced apoptosis in the rat lung. Free Radic Biol Med (2007) 0.93
Valproate population pharmacokinetics in children. J Clin Pharm Ther (1999) 0.89
Kinetics of paraquat in the isolated rat lung: Influence of sodium depletion. Xenobiotica (2006) 0.86
Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol (2003) 0.84
Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos (1999) 0.84
Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther (1993) 0.82
Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit (1992) 0.82
Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol (2002) 0.81
Pharmacokinetics of rectal ketamine in children. Br J Anaesth (1989) 0.81
Pharmacokinetics of amoxapine and its active metabolites. Int J Clin Pharmacol Ther Toxicol (1985) 0.81
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.79
Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients--a comment. Pharmacotherapy (1999) 0.78
Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit (1997) 0.78
Digoxin pharmacokinetics in patients with high serum digoxin concentrations. J Clin Pharm Ther (1993) 0.77
Bayesian forecasting in paediatric populations. Clin Pharmacokinet (1996) 0.77
Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. Pharm Res (1994) 0.76
[Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil]. Rev Clin Esp (2004) 0.76
The biotransformation kinetics of ketamine "in vitro" in rabbit liver and lung microsome fractions. Eur J Drug Metab Pharmacokinet (1986) 0.76
[Populational pharmacokinetics: An approach to the]. Enferm Infecc Microbiol Clin (2001) 0.76
[Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin]. Rev Esp Quimioter (2003) 0.76
The influence of clinical and pharmacological factors on enuresis treatment with imipramine. Br J Clin Pharmacol (1990) 0.75
Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Eur J Drug Metab Pharmacokinet (1997) 0.75
Determination of netilmicin in plasma by HPLC. J Pharm Biomed Anal (1995) 0.75
[Decision analysis in antibiotic therapy]. Enferm Infecc Microbiol Clin (1990) 0.75
Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy (1994) 0.75
[New directions in the prevention of aortic prosthesis infection using antibiotics. Cefmetazole levels in blood, abdominal wall and aorta]. Angiologia (1987) 0.75
Biotransformation kinetic of binifibrate and identification of its metabolites. Boll Chim Farm (1991) 0.75
[Pharmacokinetics of sulfachlorpyridazine]. Arch Farmacol Toxicol (1979) 0.75
Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Investig (1998) 0.75
Bioavailability of amoxapine in experimental animals. Boll Chim Farm (1986) 0.75
Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen. Methods Find Exp Clin Pharmacol (1997) 0.75
[Individualized dosage of theophylline for ambulatory asthmatic patients]. Med Clin (Barc) (1983) 0.75
Pharmacokinetic and nephrotoxic study of gentamicin in rabbits using a new dosage regimen. Eur J Drug Metab Pharmacokinet (1990) 0.75
[Relation of blood levels of amoxapine and its active metabolites to its pharmacologic response and toxicity]. Med Clin (Barc) (1985) 0.75
[Protein binding of sulphachlorpiridacine (author's transl)]. Arch Farmacol Toxicol (1979) 0.75
[Serum levels and spirometric response with sustained release theophylline]. Med Clin (Barc) (1985) 0.75
A computer program (DCN) for numerical convolution and deconvolution of pharmacokinetic functions. J Pharmacobiodyn (1992) 0.75
Population pharmacokinetic study of gentamicin and a Bayesian approach in patients with renal impairment. J Clin Pharm Ther (1989) 0.75
Analytical evaluation of TDx cyclosporine and metabolites fluorescence polarization immunoassay and comparison with the Cyclo-Trac RIA kit. J Clin Pharm Ther (1990) 0.75
Determination of low concentrations of dibenzylamine in human plasma and urine by gas chromatography with a nitrogen-phosphorus detector. J Chromatogr (1989) 0.75
[Validity of preclinical research in the development of new antibiotics. Pharmacokinetic aspects]. Enferm Infecc Microbiol Clin (1991) 0.75
Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function. Int J Clin Pharmacol Biopharm (1979) 0.75
[Follow-up of antitubercular treatment]. Rev Clin Esp (1994) 0.75
The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. J Clin Pharmacol (1995) 0.75
High levels of tricyclic antidepressants in conventional therapy: determinant factors. Int J Clin Pharmacol Ther Toxicol (1988) 0.75
Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin. Eur J Drug Metab Pharmacokinet (1998) 0.75
Dosage optimization methods applied to imipramine and desipramine in enuresis treatment. J Clin Pharm Ther (1992) 0.75
Toxicological evaluation of lactose and chitosan delivered by inhalation. J Biomater Sci Polym Ed (2008) 0.75
[Isoniazid-food interactions]. Arch Bronconeumol (1998) 0.75
Study of the disposition kinetics of the N-oxide-derivative: a metabolite of picobenzide. Eur J Drug Metab Pharmacokinet (1989) 0.75
Imidazole binding to human serum albumin. Int J Clin Pharmacol Ther Toxicol (1988) 0.75
[Therapeutic non-compliance in patients with chronic airway obstruction]. Rev Clin Esp (1987) 0.75
Distribution kinetics of netilmicin in human blister fluid: effect of renal impairment. Biopharm Drug Dispos (1991) 0.75
The phenfluramine-montmorillonite complex: adsorption and desorption. Pharm Acta Helv (1986) 0.75
IR and X-ray diffraction study of chlorpheniramine maleate-montmorillonite interaction. J Pharm Sci (1980) 0.75
Isolation and identification of the N-oxide metabolite of picobenzide in human urine. Eur J Drug Metab Pharmacokinet (1986) 0.75
Predictive techniques applied to imipramine therapeutic drug monitoring. DICP (1989) 0.75
Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. Biopharm Drug Dispos (1990) 0.75
Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes. Int J Clin Pharmacol Ther Toxicol (1987) 0.75
Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography. Am J Hosp Pharm (1992) 0.75
Population pharmacokinetics of imipramine in children. Eur J Clin Pharmacol (1992) 0.75